Shanghai Huiyu Biomedical Technology

Shanghai Huiyu Biomedical Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative transdermal drug delivery systems. The company's core technology platform focuses on soluble microneedles, which allow for the painless and efficient delivery of both small molecules and complex biologics through the skin. Their lead therapeutic candidate, HY-001, is a lidocaine-loaded microneedle patch currently being evaluated for local anesthesia and pain management applications. In addition to its pharmaceutical pipeline, which includes treatments for migraine and metabolic diseases, the company has successfully commercialized microneedle-based products for the medical aesthetics and skincare markets. Huiyu Bio is supported by prominent investors such as Sequoia China and IDG Capital, positioning it as a leader in the emerging field of advanced drug delivery in Asia. The company maintains integrated R&D and GMP-compliant manufacturing capabilities to support its transition from laboratory innovation to commercial-scale production.